Clinical Observation of Oxycodone Hydrochloride Controlled-release Tablets in the Treatment of Moderate to Severe Cancer Pain

Wen Zongqiu

Abstract:Objective To investigate the efficacy,adverse effect,and improvement on quality of life of oxycodone hydrochloride controlled-release tablets (Oxycontin) for the treatment of moderate to severe cancer pain.Methods 102 patients suffering from moderate to severe cancer pain received oral Oxycontin at an initial dosage of 5mg to 10mg every 12 hours;patients treating with morphine converted to Oxycontin in a half dosage of morphine;and those using transdermal fentanyl(Durogesic)patients would converted to Oxycontin by adjusted dosage as transdermal fentany 25.0 mcg/hour every 72 hours equal to Oxycontin 15mg every 12 hours. Dose of Oxycontin was adjusted according to pain score until patient scoringor = 2.All patient received oral Oxycontin treatment not less than fifteen days,and would be re-evaluated their pain scores,quality of life and adverse effects simultaneously. Results The ultimately daily titrated dosage of Oxycontin ranged from 20 mg to 240 mg,and the median daily dose was 50 mg. The overall response rate of pain relief was 91%,with 42% patient getting complete response,36% patient meeting obviously response,and 13% patient resulting in partial response.The analgesia by Oxycontin improved patient's quality of life significantly. The mainly side effect of Oxycontin was constipation,which could be solved after treatment.Conclusion It could bring significant analgesia and improve the patient's quality of life to treat moderate to severe cancer pain with oxycodone hydrochloride controlled-release tablets,and the side effects were tolerable.

Medicine